The Future Role of Biosimilars: An Unknown Frontier in IBD Treatment
|
|
- Sydney Lucas
- 6 years ago
- Views:
Transcription
1 The Future Role of Biosimilars: An Unknown Frontier in IBD Treatment Miguel Regueiro, MD, FACG Professor of Medicine Medical Director, IBD Center Senior Medical Lead, Specialty Homes University of Pittsburgh Medical Center Why even have this talk? Why not stick with what we know and love! 2 Copyright American College of Gastroenterology 1
2 One approach to healthcare costs is similar to this car 4 Copyright American College of Gastroenterology 2
3 Maybe we can get away with... 5 Biosimilars Biosimilars are a similar copy of an originator biologic therapy. The originator is also sometimes called the reference product or innovator. What should be the same? Strength Route of administration Effectiveness Safety profile What is different? They are NOT an identical copy in every way (glycosylation may differ) Copyright American College of Gastroenterology 3
4 Thousands of participants for disease indications such as: Rheumatoid arthritis, Crohn s, ulcerative colitis Originator Biologics Biologic developed and tested FDA Application Clinical Trials Biosimilars Biologic developed and tested FDA Application Clinical Trials Clinical trials on one or more disease indication(s) from originator Example: Rheumatoid arthritis Must demonstrate safety and effectiveness FDA and Drug Sponsor Review Meeting Biologic License Application FDA and Drug Sponsor Review Meeting Biosimilar Biologics License Application Must demonstrate high similarity to reference drug. No clinically meaningful differences Example: Approval for IBD, RA, AS Drug Approval and Labeling Drug Approval and Labeling Example: Approval for IBD, RA, AS Biosimilars Can be Extrapolated to Other Indications Comparison studies of a biosimilar that show equivalent efficacy and safety to the originator in ONE INDICATION may be EXTRAPOLATED to all indications for the originator EXAMPLE: biosimilar infliximab that works equally well in rheumatoid arthritis can be extrapolated and receive FDA approval without any additional studies for Crohn s disease, ulcerative colitis, ankylosing spondylitis, psoriasis and psoriatic arthritis. Indication 6 Indication 6 Adapted from: US Biologics Price Competition and Innovation Act of 2009 Indication 1 Indication Indication 4 Indication 2 Indication 3 Mechanism of action Pharmacokinetics Immunogenicity Toxicities Copyright American College of Gastroenterology 4
5 Interchangeable Biosimilars Interchangeable designation of biosimilars may allow for free exchange with originator biologics with no greater risk of adverse effects or diminished efficacy Could allow pharmacy substitution without prescriber intervention Subject to each state s laws and regulations governing drug FDA determines whether a biosimilar is interchangeable or not Requires studies of switching between originator and biosimilar Adapted from: US Biologics Price Competition and Innovation Act of 2009 Biosimilars in Development Over 650 biosimilars in development 1 Nearly 50% of biosimilars are in pre clinical trial stage 1 It takes 7 to 8 years to develop a biosimilar, at a cost of between $100 million and $250 million 2 1 Radar RA. Bioproc Int. 2013; 11(6): S Blackstone EA, et al. Am Health Drug Benefits. 2013;6(8): Copyright American College of Gastroenterology 5
6 Biosimilar for IBD Inflectra TM is the first FDA approved biosimilar for inflammatory bowel disease Has biosimilarity to infliximab (Remicade ) Not interchangeable Studied in: Ankylosing Spondilitis Rheumatoid Arthritis Extrapolated to: Crohn s disease (in adults and children) Ulcerative colitis (in adults) Not available yet, projected 2018 Source: accessed May, 2016 Issues with Biosimilars Risk of having the originator therapy in patient SWITCHED to the biosimilar in stable patient unknown Confusion regarding names and branding like: Potential for immunogenicity or cross reactivity unknown Means that anti drug antibodies will cross react Loss of response or allergic reaction to the originator will occur equally with the biosimilar Remicade Originator VS Remsima Biosimilar In Europe Copyright American College of Gastroenterology 6
7 HOW HAVE BIOSIMILARS PERFORMED IN IBD? IFX Biosimilar (CT P13): Efficacy Results from a National Observation Cohort Prospective, nationwide, multicenter observational cohort to assess efficacy and safety of CT P13 in CD and UC Follow up 108 weeks for CD and 54 weeks for UC Clinical disease activity assessed at each visit Biomarkers assessed every 3 months Sera for trough and antidrug antibodies obtained at baseline, 3, 6, and 12 months Imaging/endoscopy completed every 12 months Gecse K. ECCO 2015 Copyright American College of Gastroenterology 7
8 Results of IFX Biosimilar (CT P13) Significant decrease in CDAI at 2 and 6 weeks compared to baseline (p<0.001) Decrease in CRP from 23.5 mg/dl at baseline to 11.3 and 15.4 at Week 2 and 6, respectively Decrease in pmayo from 6.4 at baseline to 3.7 and 3.6 at Week 2 and 6, respectively 4 allergic reactions occurred all in patients with prior anti TNF exposure Gecse K. ECCO 2015 Efficacy and Safety of IFX Biosimilar (CT P13) in Korea Retrospective multicenter study of IFX biosimilar (CT P13) (n=106) CD (n=55) 58% IFX exposed 42% anti TNF naïve UC (n=51) 20% IFX exposed 80% anti TNF naive Limitations: No comparator studies, therefore no firm biosimilarity conclusions can be drawn. Key questions remain on switch cohort, statistical methods used and missing data, such as unknowns about whether responder analysis, LOCF, etc. that might explain such high responses Yoon Suk J, et al. ECCO 2015 Copyright American College of Gastroenterology 8
9 Efficacy of CT P13 in Anti TNF Naïve Patients at 8 Weeks Limitations: No comparator studies, therefore no firm biosimilarity conclusions can be drawn. Key questions remain on switch cohort, statistical methods used and missing data, such as unknowns about whether responder analysis, LOCF, etc. that might explain such high responses Yoon Suk J, et al. ECCO 2015 Current Studies of Biosimilars in IBD Study Population Study CRP Gecse et al. Hungary (2015) DDW Sympo Norway (2015) Jarzebicka et al. Poland (2015) Suk et al. Korea (2015) Murphy et al. Ireland (2015) CD=90 UC=51 CD=46 UC=32 CD=32 Pediatrics CD=55 UC=51 IBD=36 Infliximab biosimilar induction Biosimilar induction Switch IFX to biosimilar CT P13 Remsima switch from IFX or ADA or anti TNF naive Descriptive Inflectra=14 IFX=22 Decreased 23.5 to W2: 11.3 and W6: 15.3) Decreased Decreased (5.1 to 0.6) not reported Inflectra Increased (93%) Other Outcomes Allergic reactions 6/141 Remission CD=76% UC=56% Safe switch to biosimilar Maintenance of Remission CD=86% UC=67% Inflectra Increased surgery (29%) and readmission (80%) Copyright American College of Gastroenterology 9
10 Anti TNFs account for 20 25% of Total Costs from Biologics States with Laws about Biosimilars accessed Dec 9, 2015 Copyright American College of Gastroenterology 10
11 The Reality: Biosimilars are here Canada 4 INNs are used, when they exist. Awaiting WHO final decision. USA 1 2 FDA has not provided guidance. Recent decisions used pre fix. (tbo filgrastim, zivaflibercept) EC/EMA 3 Does not support distinguishable INNs. EMA encourages prescribing by brand name. Japan 6 Biological qualifier recommended Brazil 7 Biosimilar guidance does not address naming. Australia 5 Distinguishable nonproprietary name process implemented then halted pending WHO guidance (1) CDER Zaltrap application summary: Accessed August 1, (2) FDA Week (vol. 18, No 36, September 7, 2012) (3) Eu Comm. Pharmaceutical Committee Meeting. 23 Oct, 2013 (4) Health Canada Drug Products Database: Terminology (5) Australian TGA 17 July, Evaluation of Biosimilars (6) WHO 57 th Consultation on INNs Geneva Switzerland 2013 RDC 55/2010 Pharmacovigilance, Tracking and Traceability Company Confidential 2014 The other reality: THIS is what the Health Plans see when they see Inflammatory Bowel Disease Top 10 costs for IBD pts - #1 and 2 mostly biologic, #3 ER/Hospital if we could cut biologic cost in half.. What Types of Service do these Members Utilize? Rank Financial Service Type Total PMPM % of Total Claim Expenditure Unique Members Units/ 1,000 with at least 1 Claim % of Members in population with at 1 least 1 claim 1 Pharmacy $ % 32,591 2, % 2 Injectable Drugs $ % 4,549 1, % 3 IP Medical Surgical $ % % 4 Specialist $ % 10,553 2, % 5 Outpatient Surgery $ % 924 1, % 6 Emergency Room $ % 1,389 1, % 7 Lab Services $ % 5,785 2, % 8 PCP $ % 5,577 2, % 9 Observations $ % % 10 High Tech Radiology $ % % 29 Copyright American College of Gastroenterology 11
12 Building the IBD Home of Tomorrow A New Model for 360 o Subspecialty Patient Centered Care Miguel Regueiro, M.D. Professor of Medicine Western PA IBD Medical Home Population Copyright American College of Gastroenterology 12
13 Cost of First 100 pts: based on UPMC HP claims data from the one year prior to enrollment in the IBD medical home Total $3,685,064 Med Cost $1,348,142 PMPM $2, Proposed Three (3) Year Plan UPMC Health Plan will support the staffing for the program; adjusting based on membership Target is 350 members enrolled for the first year (900 by year 3). Expected savings anticipated from: decreased unplanned care clinical pathways to decrease variation in care biologic utilization (home infusions, biosimilars) Copyright American College of Gastroenterology 13
14 Theoretical Scenarios coming soon? The Health Plan will only approve biosimilar antitnf for your patient the biosimilar is 30% lower cost 34 yo female with severe UC in remission x 2 yrs with antitnf/aza HP: switch your patient to the biosimilar 27 yo newly dx d CD pt with perianal fistula and deep ulcers in colon/ileum HP: start your patient on the biosimilar 35 Infliximab Biosimilar is Effective and Safe When Switching from Branded Infliximab Percent of Patients Methods: Multicenter study of consecutive patients on CT P13 (infliximab (IFX) biosimilar) N=547 patients (IFX naïve, previous anti TNF exposure, and switched from IFX) Results: 311 anti TNF naïve, 139 previous anti TNF exposure (IFX=31, ADA=105, GOL=3) 97 switched from IFX to CTP Preliminary efficacy estimates* Naïve Previously exposed Switch Clinical remission at week 12 GOL, golimumab; IRR, infusion reaction rate; NS, not significant Fiorino G, et al. Presented at DDW. May Abstract Clinical remission at week 24 Infusion reactions (typically after a drug holiday) Naive vs previously exposed Infusion reactions p value Incidence IRR: 0.21 ( ) <0.01 3% Naïve vs switch IRR: 0.70 ( ) NS 7% Previously exposed vs switch Other AEs Naive vs previously exposed IRR: 3.25 ( ) < % Other AEs p value Incidence IRR: 0.54 ( ) NS 3% Naïve vs switch IRR: 1.46 ( ) NS 4% Previously exposed vs switch IRR: 2.71 ( ) NS 7% Copyright American College of Gastroenterology 14
15 Biosimilars will be a reality very soon Copyright American College of Gastroenterology 15
Naming, tracing, switching and other safety issues after 10 years learning
Naming, tracing, switching and other safety issues after 10 years learning Prof. Dr. Irene Krämer, Department of Pharmacy Johannes Gutenberg-University Medical Center, Mainz (Germany) Disclosures Speaker
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human
More informationTOP PAPERS FROM 2016: IBD & BIOSIMILARS CYNTHIA SEOW MBBS(HONS), MSC, FRACP UNIVERSITY OF CALGARY CDDW, BANFF, AB MARCH 5, 2017
TOP PAPERS FROM 2016: IBD & BIOSIMILARS CYNTHIA SEOW MBBS(HONS), MSC, FRACP UNIVERSITY OF CALGARY CDDW, BANFF, AB MARCH 5, 2017 FINANCIAL INTEREST DISCLOSURE (OVER THE PAST 24 MONTHS) Speaker: Janssen,
More informationInterchangeability, Switching and Substitution of Biotherapeutics: Clinical Issues and Challenges
Interchangeability, Switching and Substitution of Biotherapeutics: Clinical Issues and Challenges Dr. Freddy José Faccin Lazo, M.D. Global Biotherapeutics Head Global Medical Affairs Abbvie Overview Introduction
More informationBiosimilars Scientific Challenges and Implications
Biosimilars Scientific Challenges and Implications Professor Paul Declerck Laboratory for Therapeutic and Diagnostic Antibodies paul.declerck@pharm.kuleuven.be Biological medicinal product A well-defined
More informationREFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Ulcerative Colitis in the United States In 2012,
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationThe Future of the U.S. Biosimilars Market: Development, Education, and Utilization. October 18, 2016
The Future of the U.S. Biosimilars Market: Development, Education, and Utilization October 18, 2016 ABOUT THE DUKE MARGOLIS CENTER FOR HEALTH POLICY The Duke-Robert J. Margolis, MD, Center for Health Policy,
More informationBiologics in IBD: Optimizing Therapies and Emerging Agents
Optimizing Therapies and Emerging Agents Peter Mannon, MD Professor of Medicine and Microbiology UAB AGS Annual Conference July 1, 2017 Hilton Sandestin Optimizing Therapies and Emerging Agents Optimizing
More informationBIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca
BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD INFLAMMATION AND IMMUNITY IN CROHN S AND COLITIS Inflammation is the body s normal and natural
More informationDrug Development in Inflammatory Bowel Disease: The FDA Perspective
Drug Development in Inflammatory Bowel Disease: The FDA Perspective Kerry Jo Lee, M.D. Division of Gastroenterology and Inborn Errors Products U.S. Food and Drug Administration 1 Disclosure Kerry Jo Lee,
More informationREFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for Rheumatoid Arthritis in Japan The Rheumatoid Arthritis
More informationSandoz Biopharmaceuticals. Sandoz Biosimilars. From concept to reality
Sandoz Biopharmaceuticals Sandoz Biosimilars From concept to reality 2 SANDOZ BIOPHARMACEUTICALS The basics of biosimilars Biosimilars explained Biologic medicines are produced by a complex process involving
More informationBiosimilar regulation in Republic of Korea and Asia-Pacific Economic Cooperation (APEC) developments
Biosimilar regulation in Republic of Korea and Asia-Pacific Economic Cooperation (APEC) developments Ministry of Food and Drug Safety Jeewon Joung Outline I. Korean Regulatory Framework for Biosimilar
More informationBiosimilars. Their regulatory status and their use
Biosimilars Their regulatory status and their use Bruno Flamion, MD, PhD Professor of Physiology & Pharmacology, University of Namur, Belgium Past Chair of the European Medicines Agency (EMA) Scientific
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Biosimilars Committee on Rheumatologic Care Members of the American College of Rheumatology Medical Societies
More informationOriginal Article. Abstract. 1. Introduction
Journal of Crohn's and Colitis, 216, 1287 1293 doi:1.193/ecco-jcc/jjw87 Advance Access publication April 19, 216 Original Article Original Article Clinical Outcomes Following a Switch from Remicade to
More informationAmbrogio Orlando. L esperienza clinica con il biosimilare in Italia. IBD Unit U.O. Medicina Interna 2a A.O. Osp.Riuniti Villa Sofia-Cervello Palermo
Ambrogio Orlando L esperienza clinica con il biosimilare in Italia IBD Unit U.O. Medicina Interna 2a A.O. Osp.Riuniti Villa Sofia-Cervello Palermo Background and aims The monitoring of appropriateness,
More informationProfessor Kimme Hyrich, MD, PhD, FRCPC, UK
GaBI Scientific Meetings 26 January 2017, Pullman London St Pancras, London, UK ROUNDTABLE ON REGISTRIES Practical Considerations for Registries making them work Professor Kimme Hyrich, MD, PhD, FRCPC,
More informationBiosimilars are interchangeable with their reference products under the supervision of a health care person.
EXTENDING THE USE OF BIOSIMILAR DRUGS: ARE WE WILLING TO ACCEPT THE UNCERTAINTY RELATED TO SWITCHING IN ORDER TO IMPROVE PATIENT ACCESS TO MODERN MEDICINES? Tomas Tesar, PharmD, PhD, MBA, MSc Member of
More informationFormulário de acesso a dados do Registo Nacional de Doentes Reumáticos (Reuma.pt) da SPR
Formulário de acesso a dados do Registo Nacional de Doentes Reumáticos (Reuma.pt) da SPR 1. Title Efficacy and safety of biosimilar infliximab CT-P13 compared to originator infliximab in rheumatoid arthritis
More informationSurvey 1 - Rheumatoid Arthritis (RA) Patients perception on originator biologics and biosimilars
SUPPLEMENTAL MATERIAL - Perception of originator biologics and biosimilars: a survey amongst Belgian rheumatoid arthritis patients and rheumatologists BioDrugs Eline van Overbeeke 1, Birgit De Beleyr,
More informationBiosimilars: An Update on Clinical Trials (Review of Published and Ongoing Studies)
2017;25(1):57-66 REVIEW Biosimilars: An Update on Clinical Trials (Review of Published and Ongoing Studies) Rodica Olteanu, Alexandra Zota, Magda Constantin Colentina Clinical Hospital, Dermatology Department,
More informationThe Role of Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease
Review Article The Role of Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease Devika Kapuria 1* and Rajiv Chhabra 2 1 Department of Internal Medicine, University of Missouri, Kansas City, USA;
More informationBaek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
More informationPolicy considerations for originator and similar biotherapeutic products
Pharmaceuticals Policy and Law 18 (2016) 121 139 121 DOI 10.3233/PPL-160438 IOS Press Policy considerations for originator and similar biotherapeutic products Gustavo Grampp a,, Robert W. Kozak b and Thomas
More informationEmerging Medical Therapies in Inflammatory Bowel Disease
Emerging Medical Therapies in Inflammatory Bowel Disease - 2017 Nir Modiano, MD, PhD Assistant Professor of Medicine Division of Gastroenterology & Hepatology Director, Inflammatory Bowel Disease Program
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More informationTreatment: Nutrition and Medication
INFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE Treatment: Nutrition and Medication While there is no cure for Crohn s disease, there are a number of options to help treat it. The goals of treatment
More informationAssays for Immunogenicity: Are We There Yet?
Assays for Immunogenicity: Are We There Yet? Mark Wener, MD Department of Laboratory Medicine & Rheumatology Division Department of Medicine University of Washington Seattle, WA 98195 wener@uw.edu Goals:
More informationECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease An Update
Journal of Crohn's and Colitis, 2017, 26 34 doi:10.1093/ecco-jcc/jjw198 Advance Access publication December 7, 2016 ECCO Position Statement ECCO Position Statement ECCO Position Statement on the Use of
More informationCancer Vanguard. Biosimilars Trust Policy Template
Cancer Vanguard Biosimilars Trust Policy Template Aim of this document: The document provides generic guidance and outline for the development of local trust policies in relation to the adoption of biosimilars
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (FINAL) Etanercept (Erelzi Sandoz Canada Inc.) Indications: Rheumatoid Arthritis, Ankylosing Spondylitis, Polyarticular Juvenile
More informationCLINICAL DEVELOPMENT SERVICES. Immune-Mediated Inflammatory Diseases
CLINICAL DEVELOPMENT SERVICES Immune-Mediated Inflammary Diseases Table of contents 01 The new inflammation paradigm 02 Solutions for your success 03 An interconnected perspective 04 High-quality data
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/B006 Page 1 of 5 and Therapeutics Quality PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationOctober 27, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
October 27, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-N-0648: Designation of Official Names and
More informationInt. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets
Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,
More informationClinical Immunogenicity and the Biosimilar paradigm
Clinical Immunogenicity and the Biosimilar paradigm Dr Syed Numan 05 March 2015 Guiding Principles Access to safe and effective medicines is important to patients, to those who care for them and to AbbVie.
More informationDefining Clinical Benefit in Clinical Trials: FDA Perspective
Defining Clinical Benefit in Clinical Trials: FDA Perspective Jessica J. Lee, MD, MMSc Medical Team Leader Division of Gastroenterology and Inborn Errors Products Center for Drug Evaluation and Research
More informationBiosimilars in the EU
Biosimilars in the EU Information guide for healthcare professionals Prepared jointly by the European Medicines Agency and the European Commission Table of contents Foreword 2 Summary 3 Biological medicines:
More informationAdvance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?
Advance Topics in Pharmacoepidemiology Risk Management 2012 Mid-Year ISPE Meeting Miami, April 21-23, 2012 Ariel E., Arias MD, PhD - Fac. Pharmacy; Université de Montréal - Biologics & Genetic Therapies
More informationCurrent Trends and Future of Biosimilars
Current Trends and Future of Biosimilars Jian Wang, MD, PhD Chief, Clinical Evaluation Division Biologics and Genetic Therapies Directorate Health Canada Global Bio Conference 2017 June 28-30, 2017 Seoul,
More informationNOR-SWITCH: Resultater og implikasjoner. Tore K. Kvien. Dept of Rheumatology Diakonhjemmet Hospital Oslo, Norway
NOR-SWITCH: Resultater og implikasjoner Tore K. Kvien Dept of Rheumatology Diakonhjemmet Hospital Oslo, Norway Tore K. Kvien disclosures Honorarium Institutional support NOR-DMARD Presentation Advice Previous
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationKFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical
More informationType of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationBiological Qualifier An INN Proposal. Programme on International Nonproprietary Names (INN)
INN Working Doc. 14.342 Revised draft June 2015 Distr.: RESTRICTED ENGLISH ONLY Biological Qualifier An INN Proposal Programme on International Nonproprietary Names (INN) Technologies Standards and Norms
More informationREFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - US Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in the US 2012 We estimate the 2012 PsO drug
More informationIS BIOSIMILARS COMPETITIVE INTELLIGENCE DIFFERENT?
IS BIOSIMILARS COMPETITIVE INTELLIGENCE DIFFERENT? Duncan Emerton Senior Director, Syndicated Insights & Analysis FirstView (a division of FirstWord Pharma) T: +44 7964 920415 E: duncan.emerton@firstwordgroup.com
More informationWhat We Learned Running Investigator Initiated Trials
What We Learned Running Investigator Initiated Trials James D. Lewis, MD, MSCE Division of Gastroenterology Center for Clinical Epidemiology & Biostatistics University of Pennsylvania Hans Herfarth, MD,
More informationClinical Trials in Taiwan Regulatory Achievement and Current Status
Clinical Trials in Taiwan Regulatory Achievement and Current Status Hui-Po Wang, Ph.D. Director General, Bureau of Pharmaceutical Affairs, Department of Health, Taiwan Sue, Shu-Yi Chen, Pharmacist Division
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) ) ) ) ) COMPLAINT INTRODUCTION
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ABBVIE INC. and ABBVIE BIOTECHNOLOGY LTD. Plaintiffs, v. AMGEN INC. and AMGEN MANUFACTURING LTD. Defendants. ) ) ) ) ) ) ) ) ) ) ) ) Civil
More information@ALSETF #EAP2015. Jess B. Rabourn CBI Expanded Access Conference July 22, 2015
How to Win Physician Collaboration Models for Advancing Access to Lifesaving Therapies @ALSETF #EAP2015 Jess B. Rabourn CBI Expanded Access Conference July 22, 2015 How to Win Now that we want Expanded
More informationSan Francisco Health Service System
San Francisco Health Service System Pharmacy Trends Board Forum: November 10, 2016 Prepared by: Aon s Pharmacy Point of View We Believe Getting patients to the RIGHT drug at the RIGHT channel for the RIGHT
More informationThe Advent of Subsequent Entry Biologics: Biosimilars Canada. The Advent of Subsequent Entry Biologics. Biosimilars in Canada
The Advent of Subsequent Entry Biologics: Biosimilars Canada The Advent of Subsequent Entry Biologics Biosimilars in Canada Spring 2014 Author: Patrick J. Mott, MSc. Editors Allison Hillier BA, MA Heather
More informationSpecialty Drug Spending
Specialty Drug Spending The IMS Institute for Healthcare Informatics reported that spending on specialty pharmaceuticals almost doubled from 2010 to 2015, and spending on this subset of drugs was responsible
More information8/14/2017 FOLLOW-ON BIOLOGICS: HOW BIOSIMILAR ARE THEY? STEPHANIE A. KLEPSER, PHARM.D. OPTIMED SPECIALTY PHARMACY OBJECTIVES OBJECTIVES
FOLLOW-ON BIOLOGICS: HOW BIOSIMILAR ARE THEY? STEPHANIE A. KLEPSER, PHARM.D. OPTIMED SPECIALTY PHARMACY OBJECTIVES Explain how biosimilars differ from small molecule generic drugs. Discuss the FDA approval
More informationImpact of New Proposals on Name Creation for 87 th PTMG Conference Vienna, Austria
Impact of New Proposals on Name Creation for 87 th PTMG Conference Vienna, Austria Susan M. Proulx, PharmD President, Med-ERRS www.med-errs.com A subsidiary of the Institute for Safe Medication Practices
More informationReport on the Expert Consultation on Improving Access to and Use of Similar Biotherapeutic Products
Report on the Expert Consultation on Improving Access to and Use of Similar Biotherapeutic Products Salle IV, International Labour Organization, Geneva, Switzerland 2-3 May 2017 1 WHO/EMP/RHT/TSN/2017.01
More informationQuality check of spontaneous adverse drug reaction reporting forms of different countries y
pharmacoepidemiology and drug safety (2010) Published online in Wiley Online Library (wileyonlinelibrary.com).2004 ORIGINAL REPORT Quality check of spontaneous adverse drug reaction reporting forms of
More informationWHITE PAPER ON. Public Procurement of Biological Medicines
WHITE PAPER ON Public Procurement of Biological Medicines JUNE 2015 Table of contents 1. 2. 3. 4. 4.1. 4.2. 4.3. 4.3.1 4.3.2 Executive summary Introduction EU policy framework Procurement of biological
More informationHatch-Waxman: Driving Access, Savings & Innovation
Hatch-Waxman: Driving Access, Savings & Innovation Introduction Thirty years ago, Congress sought to create a balance between access to lower cost generic medicines and incentives to innovate new and better
More informationFIFARMA Position: Transparency in regulatory decision making on the approval for biosimilar products
FIFARMA Position: Transparency in regulatory decision making on the approval for biosimilar products CASSS LATAM Forum, Sep 5-6, Mexico City Thomas Schreitmueller, Co-chair FIFARMA Regulatory and Biologics
More information2016 OptumRx Trend Insights
2016 OptumRx Trend Insights TREND SUMMARY Overall trend summary This report offers our perspective of the forces driving trend and spending for 2015 vs. 2016. We define trend as growth in year-over-year
More informationREFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013 STELARA (PSORIASIS) - Executive Summary Table below presents key metrics for Stelara in the seven of the nine major pharmaceutical markets. Stelara:
More informationTHE BIOLOGIC DRUG MARKET. ebook: The current state of biologic drugs and the challenges ahead
THE BIOLOGIC DRUG MARKET 2 0 1 7 HOW DO DRUGS AND BIOLOGICS DIFFER? This ebook answers that question, and so much more. OptumRx has summarized the complex and expensive world of biologic drugs for you.
More informationFactors Supporting a Sustainable European Biosimilar Medicines Market PROJECT SUMMARY FOR EXTERNAL COMMUNICATION
Market Access Factors Supporting a Sustainable European Biosimilar Medicines Market PROJECT SUMMARY FOR EXTERNAL COMMUNICATION A study undertaken by GfK Market Access on behalf of the European Biosimilars
More informationCase 2:17-cv JCJ Document 1 Filed 09/20/17 Page 1 of 51 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA. Case No.
Case 2:17-cv-04180-JCJ Document 1 Filed 09/20/17 Page 1 of 51 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA PFIZER INC., Case No. Plaintiff, v. JURY TRIAL DEMANDED JOHNSON & JOHNSON and
More informationCORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016
CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016 Positive remimazolam data in pivotal U.S. Phase III study for procedural sedation during colonoscopy
More informationBiological Qualifier An INN Proposal. Programme on International Nonproprietary Names (INN)
INN Working Doc. 14.342 Rev. Final October 2015 Distr.: UNRESTRICTED ENGLISH ONLY Biological Qualifier An INN Proposal Programme on International Nonproprietary Names (INN) Technologies Standards and Norms
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationQuantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology
Quantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology Michael G Tovey, Director, Laboratory of Viral Oncology, Institut André Lwoff, Villejuif,
More informationPharmacovigilance Approach to Challenges with Use of Medicines. Oksana Lebega USAID SIAPS project Antalya, Turkey December 10-13, 2013
Pharmacovigilance Approach to Challenges with Use of Medicines Oksana Lebega USAID SIAPS project Antalya, Turkey December 10-13, 2013 Background Development of Pharmacovigilance (1) Growing market of pharmaceutical
More informationEFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY
EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY PREAMBLE The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the
More informationEU Update on Regulatory Developments
EU Update on Regulatory Developments Pascal Venneugues European Medicines Agency CASSS CMC Strategy Forum Europe Copenhagen, 4-6 May 2015 An agency of the European Union Overview International cooperation
More informationEU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers
Strategy for the pharmaceutical industry and biosimilars Salvatore D'Acunto European Commission Enterprise and Industry Directorate-General London, 3 April 2014 EU health policy DG Research R&D, innovation
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/94528/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE
More informationNEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY
NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY MEMORANDUM IN SUPPORT OF AN AMENDMENT TO NEW YORK S PHARMACY LAW
More informationNOTICE OF SUBSTANTIAL AMENDMENT
NOTICE OF SUBSTANTIAL AMENDMENT For use in the case of all research other than clinical trials of investigational medicinal products (CTIMPs). For substantial amendments to CTIMPs, please use the EU-approved
More informationMedical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs
Medical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs Thursday, March 10, 2016 1:00 2:30 EST 12:00 1:30 CST 11:00 12:30 MST 10:00 11:30 PST Casandra Stockman,
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous
More informationThe Worldwide Alpha-1 Antitrypsin Market. Present Situation and Future Prospects
The Worldwide Alpha-1 Antitrypsin Market Present Situation and Future Prospects 2005-2015 TABLE OF CONTENTS November 2005 TABLE OF CONTENTS Executive Summary 15 Introduction. 33 Description, Background
More informationI need a medicine while
Meeting the global challenge of unique identification of medicinal products I need a medicine while abroad Contact: Anna.Gawronska-Blaszczyk@ilim.poznan.pl www.open-medicine.eu is a project funded by the
More informationFDA Guidance, Clinical Pharmacology, and Regulatory Science
Principles of Clinical Pharmacology NIH, April 25, 2013 FDA Guidance, Clinical Pharmacology, and Regulatory Science Carl Peck, MD UCSF Center for Drug Development Science Washington DC and San Francisco
More informationOverview and Life Cycle Planning for Biosimilars
September 23, 2011 The Biosimilars i il Competition and Innovation Act: Overview and Life Cycle Planning for Biosimilars Stephen Paul Mahinka Chair, Life Sciences & Healthcare Interdisciplinary Group smahinka@morganlewis.com
More informationThe Mochida Pharmaceutical Group s Medium Term Management Plan
The Mochida Pharmaceutical Group s 15-17 Medium Term Management Plan This material is an English translation of the press release issued on April 1, 2015 in Japanese, and the Japanese release is given
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More informationEuropean Regulatory Experiences and Expectations of HCP Analysis and Control
HCP Strategy Forum, Washington DC, January 26, 2015 www.pei.de European Regulatory Experiences and Expectations of HCP Analysis and Control Blood Products: Dr. Erika Friedl, PEI (DE) Discalimer: The views
More informationHealth Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center
Health Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center Dave Bode VP, Health Care Solutions DSC Logistics April 20, 2016 Health
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationGood Clinical Practice
Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie
More informationSTATEMENT SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION AND RESEARCH U.S. FOOD AND DRUG ADMINISTRATION BEFORE THE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 STATEMENT OF SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationSupplement to Journal of The Association of Physicians of India Published on 1st of Every Month 1st May, 2017
Supplement to Journal of The Association of Physicians of India Published on 1st of Every Month 1st May, 2017 9 Use of Biologics and Biosimilars in Rheumatology Shefali Khanna Sharma Abstract Prior to
More informationBiosimilars in Emerging Markets Is It A Level Playing Field?
WHITE PAPER Biosimilars in Emerging Markets Is It A Level Playing Field? Author: RODEINA CHALLAND Executive Director, Biosimilars Development, Scientific Affairs PRA Health Sciences EXECUTIVE SUMMARY Governments,
More information